Autonomix Medical (AMIX) Form 4 Reveals Option Cancellation and Revised Holdings

Rhea-AI Filing Summary

Autonomix Medical director Lori Bisson reported changes to her derivative holdings in a Form 4. The filing discloses transactions involving two option grants with exercise prices of $26.56 and $40, covering 18,862 and 46,680 underlying shares respectively. The $26.56 option was cancelled by mutual agreement and the reporting person received no consideration for that cancellation. Both option amounts were revised to reflect a 1-for-20 reverse stock split. The filing shows direct beneficial ownership following the transactions of 47,930 and 1,250 derivative securities.

Positive

• Transparent disclosure of derivative transactions and direct beneficial ownership amounts
• Adjustments for corporate action (1-for-20 reverse split) are documented, clarifying share counts

Negative

• One option grant was cancelled with no consideration to the reporting person, reducing that option-based holding

Insights

Securities Analyst

TL;DR: Director disclosed cancellation and adjustments to option grants; remaining direct derivative holdings are reported.

The Form 4 details two derivative option transactions tied to option grants with exercise prices of $26.56 and $40 and underlying share counts of 18,862 and 46,680. The $26.56 option was explicitly cancelled by mutual agreement with no consideration paid to the reporting person. Amounts were adjusted for a prior 1-for-20 reverse split. The disclosure is specific on amounts and ownership form (direct), enabling investors to update insider-holding records without additional interpretation.

Corporate Governance Expert

TL;DR: Filing shows transparent disclosure of option cancellation and post-transaction beneficial ownership; no undisclosed consideration reported.

The document clearly identifies the reporting person as a director and lists the derivative transactions and resulting direct holdings. The cancellation of one option by mutual agreement, with no consideration to the insider, is documented and accompanied by an explicit note that option quantities were revised for a reverse split. From a governance perspective the filing satisfies disclosure requirements and leaves no material ambiguity about compensation related to the cancelled option.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Bisson Lori

(Last) (First) (Middle)

21 WATERWAY AVENUE

SUITE 300

(Street)

THE WOODLANDS TX 77380

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Autonomix Medical, Inc. [ AMIX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
08/11/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Option (Right to buy)	$26.56	08/11/2025		D			18,862(1)	06/21/2025(1)	06/21/2034	Common Stock	18,862	(1)	47,930	D
Option (Right to buy)	$40	08/11/2025		D			46,680(1)	06/30/2025(1)	06/30/2033	Common Stock	46,680	(1)	1,250(2)	D

Explanation of Responses:

1. Option represents a revised share amount and exercise price based on a 1-for-20 reverse stock split from October 25, 2024. The option was cancelled by mutual agreement of the reporting person and the Company. The reporting person received no consideration for the cancellation.

2. Amount represents a revised share amount based on a 1-for-20 reverse stock split from October 25,2024.

	/s/ Trent Smith, Attorney-in-Fact for Lori Bisson	08/13/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

Who filed the Form 4 for Autonomix Medical (AMIX)?

The Form 4 was filed on behalf of Lori Bisson, identified as a director of Autonomix Medical.

What derivative transactions are reported on the AMIX Form 4?

The filing reports transactions involving two option grants with exercise prices of $26.56 and $40, for 18,862 and 46,680 underlying shares respectively.

Was any option cancelled or modified in the AMIX filing?

Yes. The option with a $26.56 exercise price was cancelled by mutual agreement and the reporting person received no consideration for the cancellation.

How were option amounts adjusted in the filing?

Option amounts were revised to reflect a 1-for-20 reverse stock split, as stated in the explanations.

What are the reported beneficial holdings after these transactions?

The filing lists direct beneficial ownership following the transactions as 47,930 and 1,250 derivative securities.